SUMOylation involved in malignant progression of multiple tumors and SENP5 may improve the chemotherapy sensitivity of hypoxic tumors
SUMOylierung an der malignen Progression mehrerer Tumoren beteiligt und SENP5 könnte die Chemosensitivität hypoxischer Tumoren verbessern
Frontiers in Pharmacology · 05.11.2025 · 16
DOI: 10.3389/fphar.2025.1648271 ↗Auf einen Blick
SUMO-Signaling war in mehreren Tumoren aktiviert und mit schlechter Prognose verknüpft. Sauerstoff beeinflusste die Chemosensitivität über die Regulation der SUMOylierung.
Fragestellung
Welche Rolle spielt die SUMOylierung bei der Tumorprogression und bei der Chemosensitivität unter Hypoxie?
Methode
Analyse von Daten aus öffentlichen Krebsdatenbanken und in-vitro-Untersuchungen unter verschiedenen Sauerstoffbedingungen; UBC9 pharmakologisch gehemmt, SENP5 per Knockdown/Überexpression geprüft.
Ergebnisse
UBC9-Inhibition hemmte die Tumorprogression durch globale DeSUMOylierung, verursachte aber Toxizität in normalen Organoiden. SENP5 war in Tumoren überexprimiert und entfernte selektiv SUMO2/3-Modifikationen.
Schlussfolgerung der Autor:innen
Die Autor:innen sehen die Hemmung des SUMOylierungswegs als therapeutisch vielversprechend. Für eine präzisere und sicherere Strategie sei die gezielte Hemmung von Komponenten wie SENP5 wichtig.
Kernaussagen
- SUMO-Signaling war in mehreren Tumoren aktiviert
- Sauerstoff modulierte die Chemosensitivität über SUMOylierung
- UBC9-Inhibition wirkte breiter, SENP5 gezielter
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.11.2025. Verfasst von Chunyan Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Tianjin Fifth Central Hospital, Tianjin, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Tianjin Municipal Science and Technology Program, Natural Science Foundation of Tianjin Municipality.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Small ubiquitin-related modifier (SUMO), a ubiquitin-like modification protein, is implicated in the aggressive progression of various tumor types. However, a comprehensive understanding of its mechanisms and the identification of therapeutically viable targets remain challenging.
Methods
We analyzed the expression and clinical relevance of SUMO pathway components using public cancer databases (e.g., TCGA). The functional role of SUMOylation was investigated under varying oxygen conditions in vitro. The core SUMOylation enzyme UBC9 was inhibited pharmacologically with Spectinomycin B1 UBC9. The tumor-specific role of SENP5 was validated through genetic knockdown and overexpression in a panel of tumor cell lines and tumor-derived organoids. To assess the potential for off-tumor toxicity, the effects of UBC9 inhibition and SENP5 targeting were further evaluated in organoids derived from fetal mouse liver and kidney.
Results
SUMO signaling was significantly activated in multiple tumors and correlated with poor prognosis. We demonstrated that oxygen levels modulate chemotherapy sensitivity via regulation of SUMOylation. While UBC9 inhibition broadly suppressed tumor progression through global deSUMOylation, it also induced toxicity in normal organoids. In contrast, SENP5 was specifically overexpressed in tumors and mediated selective removal of SUMO2/3 modifications, affecting a narrower range of substrates.
Discussion
Our findings indicate that inhibition of the SUMOylation pathway is a promising therapeutic strategy. The broader implication of our study is that the precision and safety of this approach are contingent upon targeting specific components such as SENP5, which offers a superior therapeutic window by avoiding the adverse effects associated with global SUMOylation inhibition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Tianjin Fifth Central Hospital, Tianjin, China.
- School of Medicine, Tianjin University, Tianjin, China.
- Tianjin Key Laboratory of Epigenetics for Organ Development of Premature Infants, Tianjin Fifth Central Hospital, Tianjin, China.
- Tianjin Binhai Huangnan Plateau Medical Research Institute, Huangnan Tibetan Autonomous Prefecture People's Hospital, Huangnan Prefecture, Qinghai, China.
- Department of Pathology, Tianjin Fifth Central Hospital, Tianjin, China.
- Department of General Surgery, Peking University First Hospital, Beijing, China.
Förderung
- National Natural Science Foundation of China
- Tianjin Municipal Science and Technology Program
- Natural Science Foundation of Tianjin Municipality
Zitieren
APA
Zhang, C., Han, B., Li, Y., Wang, Y., Liu, M., Jiang, Z., Wu, W., Liu, X., Liu, Y., & Liu, M. (2025). SUMOylation involved in malignant progression of multiple tumors and SENP5 may improve the chemotherapy sensitivity of hypoxic tumors. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1648271
Vancouver
Zhang C, Han B, Li Y, Wang Y, Liu M, Jiang Z, et al. SUMOylation involved in malignant progression of multiple tumors and SENP5 may improve the chemotherapy sensitivity of hypoxic tumors. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1648271
BibTeX
@article{Zhang2025,
author = {Zhang, Chunyan and Han, Bing and Li, Yanxia and Wang, Yuxiang and Liu, Min and Jiang, Zhongmin and Wu, Wenhan and Liu, Xiaozhi and Liu, Yafei and Liu, Mingyong},
title = {SUMOylation involved in malignant progression of multiple tumors and SENP5 may improve the chemotherapy sensitivity of hypoxic tumors},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1648271}
}
EUVIMED